Liraglutide

Pal-Glu(OSu)-Ome, or Nε-palmitoyl-L-glutamic acid γ-succinimide methyl ester, is an essential intermediate in the synthesis of lipidated peptides. The palmitoyl group at the Nε position enhances the compound’s lipophilicity, while the γ-succinimide methyl ester group enables effective conjugation to various bioactive molecules. This modification contributes to the improved stability, bioavailability, and tissue-targeting properties of the resulting peptides.

This compound is widely used in pharmaceutical research and peptide drug development, particularly in the synthesis of long-acting GLP-1 receptor agonists and other peptide-based therapeutics for treating metabolic disorders such as type 2 diabetes and obesity. Its ability to enhance peptide stability and prolong therapeutic action makes it valuable in the creation of sustained-release formulations.

CAS No: 294855-90-6

>>Download COA

Application:

• Peptide Synthesis: Used in the synthesis of lipid-modified peptides with enhanced bioavailability and stability.
• Pharmaceutical Development: Plays a key role in the development of long-acting peptide drugs for treating diabetes, obesity, and other metabolic conditions.
• Drug Delivery: Improves the solubility, stability, and targeting ability of peptides in therapeutic applications.
• Biochemical Research: Investigated for its potential in modifying peptide properties for various therapeutic needs.

Packing: Customized